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A bs tr ac t
Background
Plasmacytoid dendritic cells have been implicated in the pathogenesis of systemic 
sclerosis through mechanisms beyond the previously suggested production of type I 
interferon.
Methods
We isolated plasmacytoid dendritic cells from healthy persons and from patients 
with systemic sclerosis who had distinct clinical phenotypes. We then performed 
proteome-wide analysis and validated these observations in five large cohorts of pa-
tients with systemic sclerosis. Next, we compared the results with those in patients 
with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis. 
We correlated plasma levels of CXCL4 protein with features of systemic sclerosis 
and studied the direct effects of CXCL4 in vitro and in vivo.
Results
Proteome-wide analysis and validation showed that CXCL4 is the predominant pro-
tein secreted by plasmacytoid dendritic cells in systemic sclerosis, both in circulation 
and in skin. The mean (±SD) level of CXCL4 in patients with systemic sclerosis was 
25,624±2652 pg per milliliter, which was significantly higher than the level in controls 
(92.5±77.9 pg per milliliter) and than the level in patients with systemic lupus erythe-
matosus (1346±1011 pg per milliliter), ankylosing spondylitis (1368±1162 pg per mil-
liliter), or liver fibrosis (1668±1263 pg per milliliter). CXCL4 levels correlated with skin 
and lung fibrosis and with pulmonary arterial hypertension. Among chemokines, only 
CXCL4 predicted the risk and progression of systemic sclerosis. In vitro, CXCL4 down-
regulated expression of transcription factor FLI1, induced markers of endothelial-cell 
activation, and potentiated responses of toll-like receptors. In vivo, CXCL4 induced the 
influx of inflammatory cells and skin transcriptome changes, as in systemic sclerosis.
Conclusions
Levels of CXCL4 were elevated in patients with systemic sclerosis and correlated with 
the presence and progression of complications, such as lung fibrosis and pulmonary 
arterial hypertension. (Funded by the Dutch Arthritis Association and others.)
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Systemic sclerosis (also called sclero­derma) is a complex heterogeneous fibrosing autoimmune disorder with an unknown 
pathogenesis. The way in which its three major 
pathologic hallmarks — extensive fibrosis, vas-
culopathy, and immune dysfunction — are inter-
connected is unknown. Mechanistic understand-
ing is limited, in part, by a lack of animal models 
and by clinically heterogeneous patient popula-
tions.1 This disorder is classified into two major 
subtypes on the basis of the extent of cutaneous 
fibrosis: limited cutaneous and diffuse cutane-
ous systemic sclerosis.2 Pulmonary fibrosis and 
pulmonary arterial hypertension are the two 
most serious complications — currently the ma-
jor causes of death among patients with this dis-
order. Thus, in addition to clarifying pathogenic 
mechanisms, the identification of biomarkers for 
the presence and progression of clinical compli-
cations of systemic sclerosis has potential use in 
the assessment of disease activity.
On the basis of key observations by LeRoy3 
that collagen production was increased in fibro-
blasts that were isolated from scleroderma skin 
and cultured in vitro, much of the research on 
systemic sclerosis has focused on altered fibro-
blast biology. More recent studies, however, in-
dicate that immune cells are important in patho-
genesis.4,5 Indeed, genetic association studies 
have revealed that the most highly associated 
susceptibility markers include the genes encod-
ing immune signaling molecules T-bet,6 STAT4,7,8 
and IRF58,9 and the T-cell–receptor zeta chain.8 
STAT4 and IRF5 are both implicated in the secre-
tion of type I interferon, a cytokine that has been 
shown to be present in both cutaneous and pe-
ripheral-blood mononuclear cells.10 Plasmacytoid 
dendritic cells are the major source of type I 
interferon, and as such have been implicated in 
multiple autoimmune conditions that have a 
type I interferon signature, including systemic 
lupus erythematosus,11 Sjögren’s syndrome,12 and 
rheumatoid arthritis.13 Although two studies have 
shown that serum samples obtained from patients 
with systemic sclerosis showed type I interferon–
inducing activity, the role of plasmacytoid den-
dritic cells in systemic sclerosis has not been 
fully explored.14,15 The aim of our study was to 
identify a possible role for plasmacytoid dendritic 
cells in the pathogenesis of systemic sclerosis 
that is associated with the clinical phenotype.
Me thods
Study Patients
In our study, we evaluated 779 patients with sys-
temic sclerosis — 462 with the limited cutaneous 
subtype (limited disease) and 317 with the diffuse 
cutaneous subtype (diffuse disease). Throughout 
the study, the patient cohort from the Boston 
University School of Medicine was the identifica-
tion cohort for studies of plasmacytoid dendritic 
cells and included 20 healthy donors and 53 pa-
tients with systemic sclerosis; the latter included 
16 patients with limited disease, 18 with late dif-
fuse disease (duration, >3 years), and 19 with early 
diffuse disease (duration, <2 years). In addition, 
for the chemokine analysis, plasma was obtained 
from an additional 22 healthy donors, 15 patients 
with limited disease, and 31 patients with dif-
fuse disease. The replication cohorts comprised 
patients from the University of Nijmegen, the 
Netherlands (148 patients), Lund, Sweden (197), 
Milan (120), Verona, Italy (18), Ghent, Belgium (79), 
and Houston (50). Samples from an additional 
68 patients from Milan were included to compare 
CXCL4 levels in patients with early systemic scle-
rosis with levels in patients in various phases of 
preclinical systemic sclerosis, including those with 
only Raynaud’s phenomenon with or without spe-
cific antinuclear antibodies, anti–topoisomerase 
or anti–centromere antibodies, or capillary nailfold 
lesions resembling systemic sclerosis.
For the studies of the CXCL4 expression in 
plasmacytoid dendritic cells, skin sections were 
obtained from 3 patients with early diffuse sys-
temic sclerosis from Boston University and 6 pa-
tients with late diffuse disease from the Univer-
sity of Dusseldorf, Germany. All patients met the 
preliminary criteria of the American College of 
Rheumatology for the classification of systemic 
sclerosis (Table 1).16 The clinical phenotype of the 
patients is described further in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org. All samples were obtained 
after patients provided written informed consent 
and after approval of the study by the institu-
tional review board at each participating center.
To compare CXCL4 levels in samples obtained 
from patients with systemic sclerosis with levels 
in samples from healthy donors, we obtained 
plasma samples from 257 age- and sex-matched 
healthy persons from the Nijmegen Biomedical 
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Study.17 To compare CXCL4 levels in patients with 
systemic sclerosis with levels in patients with 
other clinical conditions, we determined the levels 
of CXCL4 in stored samples from 109 patients with 
systemic lupus erythematosus who fulfilled the 
American College of Rheumatology criteria18,19 
(Table S1 in the Supplementary Appendix), from 
93 patients with ankylosing spondylitis20 (Table S2 
in the Supplementary Appendix), and from pa-
tients with various stages of liver fibrosis (see the 
Supplementary Appendix for details).
Cell-Based Studies and Measurement  
of Inflammatory Mediators
All the techniques that we used in this study are 
described in detail in the Supplementary Appen-
dix. Briefly, we performed proteome-wide analy-
sis of supernatant from plasmacytoid dendritic 
cells, using surface-enhanced laser desorption/
ionization–time-of-flight (SELDI-TOF) mass spec-
trometry. Quantification of secreted cytokines was 
performed with the use of an enzyme-linked im-
munosorbent assay or Luminex immunoassay. 
We used primary endothelial cells and peripheral 
plasmacytoid dendritic cells to study the effect of 
CXCL4 in vitro. To assess CXCL4 function in vivo, 
C57BL/6 mice were exposed to subcutaneous 
CXCL4 for further RNA and histologic analysis.
Statistical Analysis
We used Student’s t-test or the Mann–Whitney 
U test for the analysis of quantitative traits, as 
appropriate, and the Kaplan–Meier method to es-
timate survival in patients with high CXCL4 lev-
els at baseline, as compared with those with low 
CXCL4 levels, with survival time set at 24 months. 
After verifying that the proportionality of haz-
ards was not violated, we used Cox regression 
analysis to estimate the effect size of CXCL4 cat-
egorization on the basis of plasma levels on the 
time to event; results are presented as hazard 
ratios along with their asymptotic 95% confi-
dence intervals. Listwise deletion was used in 
cases with missing data.
To assess the most effective cutoff value for 
CXCL4, we used DeLong’s method to compute a 
receiver-operating-characteristic (ROC) curve. The 
area (±SE) under the ROC curve was 0.987±0.009 
(95% confidence interval [CI], 0.952 to 0.996; 
P<0.001). At the cutoff value for CXCL4 of 11,589 
pg per milliliter, the sensitivity was 100%, and 
the specificity was 94%. At the cutoff value of 
9789 pg per milliliter, the sensitivity was 100%, 
and the specificity was 93%. For a practical cutoff 
for clinical practice, we chose 10 ng per milli liter 
for CXCL4, to be conservative with respect to sen-
sitivity. P values of less than 0.05 (all two-sided) 
were considered to indicate statistical significance 
and were adjusted with the use of a Bonferroni 
correction.
R esult s
CXCL4 Secretion by Plasmacytoid Dendritic Cells
To assess the production of type I interferon by 
plasmacytoid dendritic cells, we isolated BDCA4+ 
cells from 20 healthy donors and compared re-
sults in their plasmacytoid dendritic cells with 
those in cells obtained from 54 patients with sys-
temic sclerosis: 17 with limited disease and 37 
with diffuse disease (Fig. S1A in the Supplemen-
tary Appendix). Patients with diffuse disease 
Table 1. Disease Characteristics of 779 Patients with Systemic Sclerosis.*
Characteristic
Limited Cutaneous  
Systemic Sclerosis  
(N = 462)
Diffuse Cutaneous  
Systemic Sclerosis  
(N = 317)
Female sex — no. (%) 378 (82) 218 (69)
Age at onset — yr 42.4±12.3 43.8±11.2
Disease duration — yr 9.4±8.0 5.8±6.2
Positive test for antinuclear 
antibodies — %
97 86
Modified Rodnan skin-thickness 
score†
5.4±2.4 15.9±8.2
Pulmonary arterial hypertension — % 39 23
Lung fibrosis — % 26 48
Current therapies — %
Mycophenolate mofetil  0 41
Cyclophosphamide  0 23
Prednisolone 25 30
Hydroxychloroquine 18 11
Anti–interleukin-3 antibody  0  2
Methotrexate  1  5
Tacrolimus 12  0
* Plus–minus values are means ±SD.
† P = 0.03 for the comparison between patients with diffuse disease and those 
with limited disease. There were no other significant between-group differences. 
Scores on the modified Rodnan skin-thickness scale are calculated by clinical 
palpation of 17 body areas, with the thickening of each area scored as 0 (normal), 
1 (mild), 2 (moderate), or 3 (severe).
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were further stratified according to disease dura-
tion, with 18 patients in the early-disease group 
and 19 in the late-disease group. A chromogenic 
reaction was reproducibly present in the media 
from the plasmacytoid dendritic cells obtained 
from patients with early systemic sclerosis. Mea-
surement of multiple inflammatory mediators in 
these supernatants showed almost no detectable 
production of type I interferon or other mediators, 
with differential expression of only interleukin-8 
and interleukin-6 (Fig. S1B through S1G in the 
Supplementary Appendix).
Proteome-wide measurements from eight in-
dependent experiments robustly showed that only 
plasmacytoid dendritic cells from patients with 
early systemic sclerosis secreted a unique pattern 
of peaks that were identified as CXCL4, CTAP-III, 
S100A8/9, and lysozyme (Fig. 1A, and Fig. S1H in 
the Supplementary Appendix). Confirmatory as-
sessments showed markedly increased levels of 
CXCL4 in patients with systemic sclerosis (Fig. 1B). 
Increased levels of CXCL4 messenger RNA (mRNA) 
were observed only in purified plasmacytoid den-
dritic cells, and increased CXCL4 protein expres-
sion was observed in circulating plasmacytoid 
dendritic cells (Fig. S1I and S1J) and in plasma-
cytoid dendritic cells in skin from patients with 
systemic sclerosis (Fig. 1C, and Fig S1K in the 
Supplementary Appendix).
CXCL4 in the Circulation
In the identification cohort, levels of circulating 
CXCL4 were markedly higher in patients with sys-
temic sclerosis than in healthy controls and were 
particularly high in patients with early diffuse 
disease (P<0.001 for both comparisons) (Fig. 2A). 
Increased CXCL4 levels were successfully vali-
dated in the replication cohort (which included 
86 patients with systemic sclerosis with limited 
cutaneous disease, 38 with late diffuse disease, 
and 37 with early diffuse disease) and were com-
pared with 129 age- and sex-matched healthy do-
nors and 109 patients with systemic lupus ery-
thematosus, 93 with ankylosing spondylitis, and 
93 with liver fibrosis (Fig. 2B).
In addition, in the replication cohort, there 
were clear differences between the two groups 
in previously suggested biomarkers for systemic 
sclerosis, such as CCL5,21 von Willebrand factor,22 
CCL18,23 CCL2,24 and CXCL1024 (Fig. S2B in the 
Supplementary Appendix). In an exploratory analy-
sis, we found that CXCL4 levels gradually and 
significantly increased per group in the follow-
ing order: patients with primary Raynaud’s phe-
nomenon, those with Raynaud’s phenomenon and 
positive antinuclear antibodies, and those with 
very early systemic sclerosis (Raynaud’s phenom-
enon plus anti–topoisomerase or anti–centromere 
antibodies and the presence of nailfold angiopa-
thy), whereas the levels of CCL2, CXCL10, CCL5, 
von Willebrand factor, and CCL18 did not increase 
(Fig. S2C in the Supplementary Appendix).
We next assessed the association between 
CXCL4 levels and the clinical phenotype. CXCL4 
levels correlated with the extent of skin fibrosis 
in the limited cutaneous phenotype (R2 = 0.59, 
P<0.001) and the diffuse cutaneous phenotype 
(R2 = 0.74, P<0.001). Patients with high levels of 
circulating CXCL4 (≥10 ng per milliliter), as com-
pared with those with low CXCL4 levels, had sig-
nificantly earlier evidence of lung fibrosis, as 
measured by a relative decline of more than 30% 
in the forced vital capacity (hazard ratio, 3.67; 
95% CI, 2.31 to 4.31; P<0.001) or by the presence 
of bilateral fibrosis on high-resolution computed 
tomography (CT) (hazard ratio, 2.60; 95% CI, 
1.61 to 5.26; P<0.001) (Fig. 2C). Furthermore, pa-
tients with systemic sclerosis who had evidence of 
pulmonary arterial hypertension had markedly 
increased circulating CXCL4 levels, as compared 
with those without such evidence (19,078±629 vs. 
5023±329 pg per milliliter, P<0.001). High CXCL4 
levels were associated with the earlier development 
of pulmonary arterial hypertension, as determined 
on right-heart catheterization (hazard ratio, 8.33; 
95% CI, 4.43 to 15.72; P<0.001) (Fig. 2D).
We also investigated whether CXCL4 could 
serve as a biomarker in a prospective cohort of 
79 patients who were followed for 18 months. 
Patients who had a high baseline level of CXCL4, 
as compared with other biomarkers for sys-
temic sclerosis, had a significantly faster de-
cline in diffusion capacity of the lung for 
 carbon monoxide (P = 0.002), higher prevalence 
of high-resolution CT–confirmed lung fibrosis 
(22% vs. 8%, P<0.001), and faster progression 
of skin fibrosis (P<0.001) (Fig. S2D in the Sup-
plementary Appendix). None of the other che-
mokines that were measured correlated with 
progression. Table S3 in the Supplementary Ap-
pendix provides a summary of CXCL4 plasma 
levels in all the study cohorts.
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In Vitro Studies
We examined CXCL4 in vitro using plasma ob-
tained from patients with systemic sclerosis and 
commercially available CXCL4. Both the CXCL4 
and plasma induced the secretion of endothelin 1 
and down-regulation of the transcription factor 
FLI1 in human umbilical-vein endothelial cells 
 (HUVECs) and human dermal microvascular 
endothelial cells (HDMECs). The addition of 
anti–CXCL4 antibody attenuated these responses 
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Figure 1. Identification of CXCL4 as the Major Protein Product of Plasmacytoid Dendritic Cells in Systemic Sclerosis.
Panel A shows the results of proteome-wide analysis of supernatants from plasmacytoid dendritic cells (pDC) obtained from patients 
with various subtypes of systemic sclerosis (SSc) and from healthy controls (HC). Highlighted in the larger view is the analysis of sam-
ples obtained from patients with early diffuse systemic sclerosis, showing peaks for CXCL4, connective tissue-activating peptide III 
(CTAP-III), S100A8/A9 (MRP8/14), and lysozyme. Panel B shows the level of CXCL4 in supernatants from plasmacytoid dendritic cells 
from the different groups that were investigated — 20 healthy donors, 16 patients with limited disease, 19 with late diffuse disease, and 
18 with early diffuse disease — on CXCL4-specific enzyme-linked immunosorbent assay. The horizontal lines indicate means, and I bars 
standard deviations. Panel C shows frozen skin sections from a representative patient with early diffuse disease (at left) and from a 
healthy control (at right), which were stained for the plasmacytoid dendritic-cell marker BDCA2 (red), CXCL4 (green), and DAPI-labeled 
nuclei (blue). BDCA2+ cells expressing CXCL4 are seen as orange (merged, lower panels).
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(Fig. 3A and 3B). In addition, CXCL4 inhibited 
the effect of vascular endothelial growth factor 
on the proliferation of HDMECs (P<0.001), a 
finding that we speculate may underlie the rar-
efaction of vessels in patients with systemic 
sclerosis (data not shown).
Plasmacytoid dendritic cells and their activa-
tion by toll-like receptors are thought to play a 
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Figure 2. Increased Levels of Circulating CXCL4 in Systemic Sclerosis and the Association with Lung Fibrosis and Pulmonary Arterial 
 Hypertension.
High levels of CXCL4 were observed in the circulation of patients with limited systemic sclerosis (SSc), late diffuse SSc, and early diffuse 
SSc in the identification cohort at Boston University (Panel A) and in 161 patients with corresponding subtypes of systemic sclerosis in 
two independent (Dutch and Swedish) replication cohorts, as compared with 129 age- and sex-matched healthy controls, 109 patients 
with systemic lupus erythematosus (SLE), 93 with ankylosing spondylitis (AS), and 93 with hepatic fibrosis (Panel B). The horizontal 
lines indicate means, and I bars standard deviations. Shown are the estimated times until the development of lung fibrosis (Panel C) 
and pulmonary arterial hypertension (PAH) (Panel D) within the first 24 months after the diagnosis of systemic sclerosis among pa-
tients with a high circulating CXCL4 level (≥10 ng per milliliter) and among those with a low CXCL4 level (<10 ng per milliliter).
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITEIT GENT on July 7, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
CXCL4 as a Biomarker in Systemic Sclerosis
n engl j med 370;5 nejm.org january 30, 2014 439
role in systemic sclerosis. On stimulation by li-
gands of toll-like receptors, plasmacytoid den-
dritic cells from patients with systemic sclerosis 
secreted more type I interferon than did those 
from controls, a difference that was fully re-
versed by the addition of anti–CXCL4 antibody 
or heparinase (Fig. 3C and 3D). In contrast, 
anti–CXCL12 antibody (SDF-1) did not have this 
effect (data not shown).
CXCL4 and Inflammatory Changes in Skin
To examine the possible role of CXCL4 in vivo, we 
used a recently described murine subcutaneous-
pump model.25 The subcutaneous administra-
tion of CXCL4 for 7 days resulted in a marked 
infiltration of inflammatory cells in the dermis 
and subdermis, as compared with that seen in 
mice infused with phosphate-buffered saline as a 
control (Fig. 4A and 4B). In addition, CXCL4 ad-
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Figure 3. Changes in Endothelial Cells and Augmented Responses in Toll-Like Receptors Induced by CXCL4.
The addition of lipopolysaccharide (LPS), low and high levels of CXCL4, and plasma obtained from a patient with 
diffuse systemic sclerosis (SSc) induce the secretion of endothelin 1 by human umbilical-vein endothelial cells, reac-
tions that were attenuated by the addition of a neutralizing antibody against CXCL4 (Panel A). In five independent 
experiments, CXCL4 was shown to reduce the expression of transcription factor FLI1 (P<0.001) and induce the ex-
pression of endothelin 1 (ET-1) (P =0.003), both on the RNA and protein level, in human dermal microvascular endo-
thelial cells (Panel B). The expression level for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was set at 1. 
On stimulation with ligands of toll-like receptors (TLR) (including R848, CpG, and CpG control), plasmacytoid den-
dritic cells from patients with systemic sclerosis secreted more interferon α (a type I interferon) than did controls 
(Panel C). This reaction was fully reversed by the addition of anti–CXCL4 antibody (Panel D). The culture medium 
was RPMI-1640 with 10% fetal-calf serum. All values are expressed as means; T bars represent standard deviations.
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ministration resulted in a significant increase in 
the thickness of dermal and subdermal layers 
after 7 days (Fig. 4C). CXCL4-induced dermal 
thickening was also observed in a longer, 28-day 
model of daily subcutaneous injection (Fig. S3D 
in the Supplementary Appendix). The influx of 
inflammatory cells was confirmed by an in-
creased number of dermal CD45+ cells in the 
CXCL4-treated skin, as well as increased expres-
sion of CD45 mRNA (Fig. 4D). Furthermore, we 
observed that CXCL4 induced the expression of 
the highly proinflammatory CCL2 in the two 
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models (Fig. 4E, and Fig. S3F in the Supplementary 
Appendix). During an investigation of the gene-
expression profile in mice that were treated with 
CXCL4 for 7 days, we found increased mRNA ex-
pression of tumor necrosis factor α, IFIT1, and 
MX2, the products of type I interferon-inducible 
genes; of the profibrotic marker PAI-1; and of the 
antiangiogenic factor thrombospondin 1 (Fig. S3A, 
S3B, and S3C in the Supplementary Appendix).
Discussion
In this study, we found that CXCL4 levels in pa-
tients with systemic sclerosis not only correlate 
strongly with both skin and pulmonary disease 
but also appear to predict progression in system-
ic sclerosis phenotypes. Collectively, the identifi-
cation of CXCL4 as a marker for fibrosis and pul-
monary arterial hypertension may be helpful in 
early diagnosis and risk assessment, an important 
factor in patients who require aggressive treat-
ment. CXCL4 was one of the most highly and dif-
ferentially expressed genes in a genomewide as-
sociation study involving patients with systemic 
sclerosis who had pulmonary arterial hypertension 
and idiopathic pulmonary arterial hypertension, as 
compared with healthy controls.26
CXCL4 is a 70-amino acid, lysine-rich, 7.8-kDa 
protein that was first identified as a product of 
megakaryocytes and comprises 2 to 3% of the 
protein content of activated platelets.27 CXCL4 is 
generally well accepted as one of the most potent 
antiangiogenic chemokines, influencing angio-
genesis through an integrin-dependent mecha-
nism.28 The high levels of CXCL4 that were 
found in patients with systemic sclerosis are of 
great interest, since plasma obtained from these 
patients also showed antiangiogenic activity, 
and the disease is characterized by rarefaction of 
vessels despite the presence of multiple proangio-
genic factors.
In addition to its antiangiogenic activity, CXCL4 
inhibits the expression of the antifibrotic cyto-
kine interferon-γ (a type 1 helper T cell) and 
up-regulates profibrotic cytokines interleukin-4 
and interleukin-13 (type 2 helper T cells).29 It 
also stimulates the proliferation of T regulatory 
cells with impaired suppressive function.30 Such 
data might indicate that the high levels of 
CXCL4 in patients with systemic sclerosis could 
be linked to features of immune dysfunction 
that have been observed in the disease.31 Accu-
mulating evidence suggests a role for CXCL4 in 
other chronic fibroproliferative and inflamma-
tory conditions. CXCL4 was shown to be an im-
portant mediator in atherosclerosis, both in vivo 
and in vitro,32 and increased CXCL4 levels have 
been associated with progressive liver fibrosis.33  
Intriguingly, despite the fact that CXCL4 induced 
skin inflammation in vivo in mice, fibrosis was 
not observed. In this light, it is tempting to 
speculate that although CXCL4 may sensitize 
various cells to inflammatory stimuli, culminat-
ing in fibrosis, the presence of CXCL4 alone is 
not sufficient. This hypothesis is supported by 
our observation that increased levels of CXCL4 
were found in patients with Raynaud’s phenom-
enon, most of whom do not have progression to 
systemic sclerosis.
Figure 4 (facing page). Inflammatory Skin Changes 
Mimicking Those in Systemic Sclerosis Induced  
by CXCL4 In Vivo in Mice.
Panels A and B show the results of histologic analyses 
of skin from wild-type C57BL/6 mice that were treated 
with phosphate-buffered saline (PBS) as a control 
(Panel A) or with CXCL4 (Panel B) for 7 days with the 
use of a subcutaneous-pump model, shown at 4× and 
20× magnification (hematoxylin and eosin, left; CD45 
immunohistochemical staining, right). The murine 
sample that was treated with CXCL4 shows marked 
 infiltration of inflammatory cells in the dermis and 
subdermis, as compared with the control sample. 
 Panel C shows quantification of the thickening of skin 
layers after CXCL4 treatment for 7 days with the use of 
the pump model, as compared with the PBS controls. 
Shown are mean values for three analyses in each 
group, with T bars indicating standard errors. Panel D 
shows the quantification of infiltrating immune cells 
after 7-day exposure to CXCL4 or PBS, in which CD45+ 
cells in the dermis were counted after immunohisto-
chemical staining; the means of three analyses per 
group are shown (at left). In addition, the influx of in-
flammatory cells is confirmed by increased CD45 mes-
senger RNA (mRNA) expression in CXCL4-exposed skin 
isolated from the distal or proximal (local) area to the 
pump outlet, as measured on quantitative polymerase-
chain-reaction (PCR) assay (at right). In Panels C and D, 
a single asterisk denotes P<0.05 for the between-group 
comparison; double asterisks denote P<0.01. Panel E 
shows the mRNA expression of proinflammatory marker 
CCL2  induced after 7-day exposure to CXCL4, as com-
pared with PBS, also measured on quantitative PCR 
assay. In  Panels D and E, the mRNA analyses included 
4 samples for PBS and 7 samples for CXCL4. The hori-
zontal lines indicate means, and I bars standard errors.
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Our data from cell culture and the murine 
model lead us to speculate that plasmacytoid 
dendritic cells, through the production of CXCL4, 
are pivotal in the onset and perpetuation of 
systemic sclerosis. In this respect, the down-
regulation of FLI1 is of particular interest, since 
selective endothelial-cell deletion of Fli-1 in mice 
leads to down-regulated expression of classic 
endothelial-cell markers, which are also seen to be 
down-regulated in the vasculature of patients with 
systemic sclerosis. The phenotype of Fli-1 knock-
out mice indicates a profound role for Fli-1 in 
vessel formation, maturation, and stabilization.34 
In addition, CXCL4 induces the expression of 
thrombospondin 1 and attenuates the effects of 
vascular endothelial growth factor. These ob-
servations might explain the absence of neovas-
cularization in systemic sclerosis, despite the 
presence of high levels of vascular endothelial 
growth factor. Thus, we speculate that CXCL4 may 
play a major role in vasculopathy associated with 
systemic sclerosis through altered FLI1 expression. 
The effect of FLI1 expression on fibroblasts may 
also be important, since FLI1 regulates elevated 
collagen synthesis, the hallmark of fibrosis.35
Several previous small studies have hinted at 
increased levels of CXCL4 and other inflamma-
tory markers in the circulation of patients with 
systemic sclerosis.23,24,36­39 In those studies, the 
observed CXCL4 levels were attributed to platelet 
activation, a conclusion inconsistent with increased 
mRNA expression by peripheral-blood mono-
nuclear cells, increased secretion of CXCL4 by 
plasmacytoid dendritic cells, and a lack of as-
sociation between increased β-thromboglobulin 
levels and increased CXCL4 levels in patients with 
systemic sclerosis. Our data show that CXCL4 
levels correlated highly with disease phenotype 
and disease progression in five large, indepen-
dent, and clinically well-characterized patient 
cohorts, whereas levels of CCL2, CXCL10, CCL5, 
von Willebrand factor, and CCL18 did not show 
such correlation.
Taken together, our observations suggest that 
CXCL4 and plasmacytoid dendritic cells are cen-
tral to the pathogenesis of systemic sclerosis. 
The levels of CXCL4 correlated well with the 
level of fibrosis and the occurrence and progres-
sion of pulmonary arterial hypertension, the 
two clinical hallmarks of this disorder. CXCL4 
levels were also increased in several other fi-
brosing or inflammatory conditions, suggesting 
that CXCL4 may play a role in many pathologic 
conditions.
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